Migdal Insurance & Financial Holdings Ltd. Sells 3,652,200 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Migdal Insurance & Financial Holdings Ltd. decreased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 12.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,466,010 shares of the company's stock after selling 3,652,200 shares during the period. Teva Pharmaceutical Industries makes up about 7.4% of Migdal Insurance & Financial Holdings Ltd.'s holdings, making the stock its biggest position. Migdal Insurance & Financial Holdings Ltd. owned approximately 2.25% of Teva Pharmaceutical Industries worth $458,896,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of TEVA. Atria Investments Inc increased its holdings in shares of Teva Pharmaceutical Industries by 135.4% in the 3rd quarter. Atria Investments Inc now owns 30,856 shares of the company's stock valued at $556,000 after purchasing an additional 17,746 shares in the last quarter. Greenwood Capital Associates LLC acquired a new position in Teva Pharmaceutical Industries during the third quarter worth about $4,267,000. Catalyst Capital Advisors LLC purchased a new position in Teva Pharmaceutical Industries in the third quarter valued at about $2,019,000. National Pension Service increased its holdings in Teva Pharmaceutical Industries by 107.3% in the third quarter. National Pension Service now owns 3,170,640 shares of the company's stock valued at $57,135,000 after buying an additional 1,640,940 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its position in shares of Teva Pharmaceutical Industries by 73.9% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 465,032 shares of the company's stock valued at $8,380,000 after acquiring an additional 197,585 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Barclays upped their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, October 23rd. UBS Group raised their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $19.67.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded down $0.39 during trading on Friday, hitting $17.11. The stock had a trading volume of 6,225,171 shares, compared to its average volume of 6,402,547. Teva Pharmaceutical Industries Limited has a 1-year low of $8.55 and a 1-year high of $19.31. The stock has a market cap of $19.38 billion, a price-to-earnings ratio of -20.13, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87. The company's 50 day moving average price is $17.94 and its two-hundred day moving average price is $17.15. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.59 and a current ratio of 0.89.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.